775 related articles for article (PubMed ID: 18835762)
1. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.
File TM; Monte SV; Schentag JJ; Paladino JA; Klugman KP; Lavin B; Yu VL; Singer ME; Adelman MH
Int J Antimicrob Agents; 2009 Jan; 33(1):58-64. PubMed ID: 18835762
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
3. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease.
Conte JE; Golden JA; McIver M; Little E; Zurlinden E
Int J Antimicrob Agents; 2007 Nov; 30(5):422-7. PubMed ID: 17716873
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
Noreddin AM; Marras TK; Sanders K; Chan CK; Hoban DJ; Zhanel GG
Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
Bhavnani SM; Forrest A; Hammel JP; Drusano GL; Rubino CM; Ambrose PG
Diagn Microbiol Infect Dis; 2008 Sep; 62(1):99-101. PubMed ID: 18583085
[TBL] [Abstract][Full Text] [Related]
6. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
Yoo BK; Triller DM; Yong CS; Lodise TP
Ann Pharmacother; 2004; 38(7-8):1226-35. PubMed ID: 15187209
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein velocity following antibiotics in patients with chronic obstructive pulmonary disease exacerbation and community acquired pneumonia.
Justo D; Lachmi S; Saar N; Joffe E; Atzmony L; Mashav N; Henis O; Sade B; Chundadze T; Steinvil A; Paran Y
Eur J Intern Med; 2009 Sep; 20(5):518-21. PubMed ID: 19712857
[TBL] [Abstract][Full Text] [Related]
8. Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience.
Ioachimescu OC; Ioachimescu AG; Iannini PB
Int J Antimicrob Agents; 2004 Nov; 24(5):485-90. PubMed ID: 15519482
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic resistance in sputum isolates of Streptococcus pneumoniae in chronic obstructive pulmonary disease is related to antibiotic exposure.
Desai H; Richter S; Doern G; Heilmann K; Dohrn C; Johnson A; Brauer A; Murphy T; Sethi S
COPD; 2010 Oct; 7(5):337-44. PubMed ID: 20854048
[TBL] [Abstract][Full Text] [Related]
11. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia.
Jover F; Cuadrado JM; Andreu L; Martínez S; Cañizares R; de la Tabla VO; Martin C; Roig P; Merino J
Eur J Intern Med; 2008 Jan; 19(1):15-21. PubMed ID: 18206596
[TBL] [Abstract][Full Text] [Related]
13. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance.
Schentag JJ; Birmingham MC; Paladino JA; Carr JR; Hyatt JM; Forrest A; Zimmer GS; Adelman MH; Cumbo TJ
Semin Respir Infect; 1997 Dec; 12(4):278-93. PubMed ID: 9436955
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of community-acquired pneumonia--treatment].
Andersen LV; Brock B; Jakobsen P; Nielsen LP
Ugeskr Laeger; 2008 Jan; 170(3):127-30. PubMed ID: 18208726
[TBL] [Abstract][Full Text] [Related]
15. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
Cantón R; Lode H; Graninger W; Milkovich G
Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S115-27. PubMed ID: 16904873
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and clinical outcomes of penicillin resistant S. pneumoniae community-acquired pneumonia in Khon Kaen, Thailand.
Reechaipichitkul W; Assawasanti K; Chaimanee P
Southeast Asian J Trop Med Public Health; 2006 Mar; 37(2):320-6. PubMed ID: 17124993
[TBL] [Abstract][Full Text] [Related]
18. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
Stass H; Dalhoff A
Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
[TBL] [Abstract][Full Text] [Related]
19. Serum hydrogen sulfide as a novel marker predicting bacterial involvement in patients with community-acquired lower respiratory tract infections.
Chen YH; Yao WZ; Gao JZ; Geng B; Wang PP; Tang CS
Respirology; 2009 Jul; 14(5):746-52. PubMed ID: 19659653
[TBL] [Abstract][Full Text] [Related]
20. Bacteriological differences between COPD exacerbation and community-acquired pneumonia.
Li XJ; Li Q; Si LY; Yuan QY
Respir Care; 2011 Nov; 56(11):1818-24. PubMed ID: 21605476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
